ProCE Banner Activity

My Thoughts on Managing Patients With CML and Comorbidities

Clinical Thought
In this commentary, I discuss management of patients with CML and comorbidities, including risk assessment, treatment selection, and drug–drug interactions.

Released: November 03, 2021

Expiration: November 02, 2022

No longer available for credit.

Share

Faculty

Jorge Cortes

Jorge Cortes, MD

Professor of Medicine
Deputy Chair, Department of Leukemia
M.D. Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Faculty Disclosure

Primary Author

Jorge Cortes, MD

Professor of Medicine
Deputy Chair, Department of Leukemia
M.D. Anderson Cancer Center
Houston, Texas

Jorge Cortes, MD, has disclosed that he has received contracted research and consulting fees from Bio-Path Holdings, Novartis, Pfizer, and Sun Pharma.

Staff Disclosure

Staff

Jerfiz Constanzo, PhD, MBA

Scientific Director

Jerfiz Constanzo, PhD, has no relevant conflicts of interest to report.

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.